EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma

Eden Biltibo, Rajshekhar Chakraborty, Michael R Bishop iD

American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)

DOI: 10.1200/edbk-26-517460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Eden Biltibo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies (BsAb) are a class of T-cell–redirecting therapies used in a variety of advanced malignancies. BsAb can be associated with clinically significant toxicities, including cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections. CRS occurs in up to two thirds of patients and can be associated with ICANS in rare cases. CRS is best treated with tocilizumab, while glucocorticoids are effective in treating both. BsAb-associated CRS and ICANS are mostly low-grade and are confined to the step-up and first full doses. However, the risk of infection persists throughout BsAb therapy and is the leading cause of nonrelapse mortality, particularly with B-cell maturation antigen (BCMA)–targeting BsAbs, due to profound B-cell and plasma cell depletion, resulting in near-universal hypogammaglobulinemia. Infection risk is also increased due to cytopenias, neutropenia and lymphopenia, occurring during the first 6 months of BsAb therapy. Current infection prophylaxis guidelines recommend universal herpes simplex virus, varicella zoster virus, and Pneumocystis jirovecii pneumonia prophylaxis, with primary intravenous immunoglobulin prophylaxis strongly recommended for BCMA-targeting BsAbs. A few other acute toxicities associated with BsAbs include infusion-related reactions generally noted very early (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaAntineoplastic Agents, ImmunologicalHumansCytokine Release SyndromeDisease Management

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN.
  • Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.
  • The David and Etta Jonas Center for Cellular Therapy, Chicago, IL.
  • Hematopoietic Cellular Therapy Program, University of Chicago, Chicago, IL.

ORCID-Profile: Michael R Bishop

Zitieren

APA

Biltibo, E., Chakraborty, R., & Bishop, M. R. (2026). Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-517460

Vancouver

Biltibo E, Chakraborty R, Bishop MR. Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-517460

BibTeX
@article{Biltibo2026,
  author = {Biltibo, Eden and Chakraborty, Rajshekhar and Bishop, Michael R},
  title = {Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1200/edbk-26-517460}
}
Kostenlos starten →